PCVX Novinky na Forexe

Vaccine maker Vaxcyte, Inc. (PCVX) announced Thursday that the U.S. Food and Drug Administration (FDA) has cleared the Company's adult Investigational New Drug (IND) application for VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD).